Nifty
Sensex
:
:
23118.60
74003.82
-279.50 (-1.19%)
-777.94 (-1.04%)

Pharmaceuticals & Drugs

Rating :
72/99

BSE: 543245 | NSE: GLAND

2895.50
15-Sep-2026
  • Open
  • High
  • Low
  • Previous Close
  •  2930
  •  2940
  •  2856.9
  •  2922.30
  • Volume
  • Traded Value (lacs)
  • 52 Week High
  • 52 Week Low
  •  497958
  •  1441792553.6
  •  3042
  •  1573.6

Stock Summary

  • Market Cap(Crs)
  • Stock P:E
  • Face Value
  • 47,530.55
  • 42.11
  • 1
  • Enterprise Value(Crs)
  • Dividend Yield
  • Price:Book Value
  • 44,414.81
  • 0.69%
  • 4.47

Shareholding Pattern

  • Promoter
  • Corporate
  • Public
  • 51.77%
  • 5.02%
  • 3.50%
  • FII
  • DII
  • Others
  • 8.74%
  • 29.51%
  • 1.46%

Chart

Price | P:E | P:BV | EV:EBITDA | MCap:Sales | EPS

Revenue CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 11.90
  • 7.88
  • 4.32

EBITDA CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 10.28
  • 1.53
  • 4.10

PAT CAGR (%)

  • 10 Years
  • 5 Years
  • 3 Years
  • 12.13
  • -3.25
  • 9.97

P:E (Median)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 38.38
  • 39.94

P:BV (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 4.17
  • 3.35

EV:EBITDA (Average)

  • 8 Years
  • 5 Years
  • 3 Years
  • -
  • 20.30
  • 18.46

Earnings Forecasts:

(Updated: 12-09-2026)
Description
2026
2027
2028
2029
Adj EPS
65
13
26.31
56.55
P/E Ratio
44.55
222.73
110.05
51.20
Revenue
32.98
27.11
22.69
6355.4
EBITDA
7342.07
8320.55
9481.76
1538.11
Net Income
1909.92
2246.56
2666.51
932.49
ROA
1194.74
1454.54
1702.76
8.51
P/B Ratio
-0.82
-0.64
-0.50
4.85
ROE
3.56
3.21
0.7
9.88
FCFF
11.19
12.2
13.63
533.23
FCFF Yield
469.77
913.21
1006.93
1.43
Net Debt
1.26
2.45
2.7
-2585.17
BVPS
-3528.34
-4533.64
-5799.77
596.4

Quarterly Results

Consolidated Figures in Rs. Crores /

Standalone
Description
Jun 26
Jun 25
Var%
Mar 26
Mar 25
Var%
Dec 25
Dec 24
Var%
Sep 25
Sep 24
Var%
Net Sales
1,800.27
1,505.62
19.57%
1,742.79
1,424.91
22.31%
1,695.36
1,384.05
22.49%
1,486.88
1,405.83
5.77%
Expenses
1,310.90
1,137.86
15.21%
1,229.77
1,077.39
14.14%
1,260.49
1,024.10
23.08%
1,172.99
1,108.78
5.79%
EBITDA
489.37
367.76
33.07%
513.02
347.52
47.62%
434.88
359.96
20.81%
313.89
297.06
5.67%
EBIDTM
27.18%
24.43%
29.44%
24.39%
25.65%
26.01%
21.11%
21.13%
Other Income
61.23
57.53
6.43%
111.47
44.03
153.17%
63.17
58.49
8.00%
84.16
59.66
41.07%
Interest
4.36
11.50
-62.09%
10.03
7.45
34.63%
3.93
22.82
-82.78%
7.82
6.11
27.99%
Depreciation
111.26
101.05
10.10%
108.66
95.76
13.47%
107.65
96.33
11.75%
106.31
93.83
13.30%
PBT
434.98
312.74
39.09%
505.80
288.33
75.42%
362.13
299.30
20.99%
283.92
256.78
10.57%
Tax
118.02
97.26
21.34%
139.12
101.79
36.67%
100.65
94.61
6.38%
100.23
93.25
7.49%
PAT
316.96
215.48
47.09%
366.68
186.54
96.57%
261.48
204.69
27.74%
183.68
163.53
12.32%
PATM
17.61%
14.31%
21.04%
13.09%
15.42%
14.79%
12.35%
11.63%
EPS
19.21
13.08
46.87%
22.26
11.32
96.64%
15.87
12.42
27.78%
11.15
9.93
12.29%

Annual Results

Standalone Figures in Rs. Crores /

Consolidated
Description
TTM
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Net Sales
6,725.30
6,430.65
5,616.50
5,664.72
3,624.60
4,400.71
3,462.88
2,633.24
Net Sales Growth
17.57%
14.50%
-0.85%
56.29%
-17.64%
27.08%
31.51%
 
Cost Of Goods Sold
2,346.13
2,242.93
2,090.38
2,173.09
1,685.42
2,109.22
1,219.00
836.07
Gross Profit
4,379.17
4,187.72
3,526.12
3,491.63
1,939.17
2,291.49
2,243.88
1,797.18
GP Margin
65.11%
65.12%
62.78%
61.64%
53.50%
52.07%
64.80%
68.25%
Total Expenditure
4,974.15
4,801.11
4,347.58
4,331.65
2,599.84
2,890.56
2,160.65
1,677.77
Power & Fuel Cost
-
202.85
199.15
229.99
124.84
95.05
74.58
78.50
% Of Sales
-
3.15%
3.55%
4.06%
3.44%
2.16%
2.15%
2.98%
Employee Cost
-
1,628.84
1,401.56
1,256.89
403.26
338.57
311.36
277.66
% Of Sales
-
25.33%
24.95%
22.19%
11.13%
7.69%
8.99%
10.54%
Manufacturing Exp.
-
407.61
347.18
327.19
194.23
179.85
436.84
391.88
% Of Sales
-
6.34%
6.18%
5.78%
5.36%
4.09%
12.61%
14.88%
General & Admin Exp.
-
211.87
206.62
217.36
120.53
94.28
58.66
57.77
% Of Sales
-
3.29%
3.68%
3.84%
3.33%
2.14%
1.69%
2.19%
Selling & Distn. Exp.
-
29.75
27.48
37.46
27.03
40.98
36.69
17.08
% Of Sales
-
0.46%
0.49%
0.66%
0.75%
0.93%
1.06%
0.65%
Miscellaneous Exp.
-
77.25
75.20
89.66
44.53
32.61
23.51
18.82
% Of Sales
-
1.20%
1.34%
1.58%
1.23%
0.74%
0.68%
0.71%
EBITDA
1,751.16
1,629.54
1,268.92
1,333.07
1,024.76
1,510.15
1,302.23
955.47
EBITDA Margin
26.04%
25.34%
22.59%
23.53%
28.27%
34.32%
37.61%
36.28%
Other Income
320.03
316.33
213.61
170.24
240.46
223.94
134.78
139.17
Interest
26.14
33.28
42.00
26.20
7.45
5.24
3.41
7.18
Depreciation
433.88
423.67
377.87
344.57
146.74
110.30
98.78
94.59
PBT
1,586.83
1,488.93
1,062.66
1,132.54
1,111.04
1,618.55
1,334.81
992.87
Tax
458.02
437.26
364.13
360.08
273.54
406.89
337.85
220.01
Tax Rate
28.86%
29.86%
34.27%
31.79%
25.94%
25.14%
25.31%
22.16%
PAT
1,128.80
1,027.32
698.53
772.46
781.04
1,211.66
996.96
772.86
PAT before Minority Interest
1,128.80
1,027.32
698.53
772.46
781.04
1,211.66
996.96
772.86
Minority Interest
0.00
0.00
0.00
0.00
0.00
0.00
0.00
0.00
PAT Margin
16.78%
15.98%
12.44%
13.64%
21.55%
27.53%
28.79%
29.35%
PAT Growth
46.55%
47.07%
-9.57%
-1.10%
-35.54%
21.54%
29.00%
 
EPS
68.41
62.26
42.34
46.82
47.34
73.43
60.42
46.84

Results Balance Sheet

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Shareholder's Funds
10,357.95
9,150.74
8,723.84
7,958.72
7,157.62
5,903.24
3,646.24
Share Capital
16.48
16.48
16.47
16.47
16.43
16.36
15.49
Total Reserves
10,295.95
9,134.21
8,705.99
7,940.59
7,127.95
5,861.46
3,614.26
Non-Current Liabilities
482.17
457.27
488.60
89.68
93.97
80.31
80.78
Secured Loans
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Unsecured Loans
69.92
77.66
106.54
3.26
3.82
3.93
4.07
Long Term Provisions
195.64
145.99
137.21
0.00
0.00
0.00
0.00
Current Liabilities
1,608.40
1,564.85
1,398.36
729.13
582.02
512.53
359.02
Trade Payables
833.87
820.41
767.75
587.35
462.85
396.35
249.09
Other Current Liabilities
657.53
619.87
520.07
109.48
76.42
62.36
81.73
Short Term Borrowings
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Short Term Provisions
117.00
124.56
110.54
32.30
42.75
53.82
28.20
Total Liabilities
12,448.52
11,172.86
10,610.80
8,777.53
7,833.61
6,496.08
4,086.04
Net Block
4,492.33
4,147.23
3,946.75
1,570.55
1,502.19
954.23
968.10
Gross Block
6,784.55
5,613.37
5,011.68
2,294.95
2,081.32
1,430.70
1,347.81
Accumulated Depreciation
2,292.22
1,466.14
1,064.93
724.41
579.13
476.46
379.71
Non Current Assets
4,921.74
4,389.91
4,965.66
1,876.73
1,981.54
1,372.44
1,239.75
Capital Work in Progress
342.18
150.56
237.88
177.22
190.75
337.81
188.47
Non Current Investment
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Long Term Loans & Adv.
83.07
87.69
119.43
128.96
286.40
77.97
81.52
Other Non Current Assets
4.16
4.43
661.59
0.00
2.21
2.43
1.66
Current Assets
7,526.78
6,782.94
5,645.15
6,900.81
5,852.08
5,123.64
2,846.29
Current Investments
0.00
0.00
0.00
0.00
154.87
0.00
0.00
Inventories
1,743.89
1,685.22
1,655.24
1,945.30
1,185.67
1,275.17
756.28
Sundry Debtors
1,891.38
1,516.53
1,558.69
871.39
1,074.81
670.97
601.78
Cash & Bank
3,359.11
2,556.21
1,839.43
3,770.68
3,093.44
3,005.75
1,325.19
Other Current Assets
532.41
149.85
102.61
91.00
343.30
171.75
163.03
Short Term Loans & Adv.
404.00
875.13
489.19
222.44
246.55
87.60
91.80
Net Current Assets
5,918.38
5,218.09
4,246.79
6,171.68
5,270.05
4,611.11
2,487.27
Total Assets
12,448.52
11,172.85
10,610.81
8,777.54
7,833.62
6,496.08
4,086.04

Cash Flow

Standalone Figures in Rs. Crores /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Cash From Operating Activity
1,031.39
914.73
996.80
363.97
790.77
604.93
700.93
PBT
1,464.58
1,062.66
1,132.54
1,054.58
1,618.55
1,334.81
992.87
Adjustment
276.75
211.94
223.60
38.19
-28.27
17.30
32.15
Changes in Working Capital
-254.50
-6.06
-53.20
-417.94
-393.01
-435.76
-79.94
Cash after chg. in Working capital
1,486.84
1,268.53
1,302.95
674.83
1,197.28
916.35
945.07
Interest Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Tax Paid
-455.45
-353.80
-306.15
-310.87
-406.51
-311.43
-244.14
Other Direct Exp. Paid
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Extra & Other Items
0.00
0.00
0.00
0.00
0.00
0.00
0.00
Cash From Investing Activity
137.73
1,704.74
-1,756.91
1,208.19
-1,002.62
-1,524.00
-766.08
Net Fixed Assets
-212.08
-140.33
-227.74
-200.10
-503.56
-232.23
Net Investments
-502.98
-403.83
-2,377.58
154.87
-162.48
-0.55
Others
852.79
2,248.90
848.41
1,253.42
-336.58
-1,291.22
Cash from Financing Activity
-416.97
-433.48
-799.42
14.92
34.90
1,238.46
-6.87
Net Cash Inflow / Outflow
752.14
2,185.99
-1,559.53
1,587.08
-176.95
319.39
-72.01
Opening Cash & Equivalents
2,556.21
357.09
1,908.89
318.82
492.46
169.50
236.40
Closing Cash & Equivalent
3,359.11
2,556.21
357.09
1,908.89
318.82
492.46
169.50

Financial Ratios

Standalone /

Consolidated
Description
Mar 26
Mar 25
Mar 24
Mar 23
Mar 22
Mar 21
Mar 20
Book Value (Rs.)
625.91
555.40
529.56
483.12
434.84
359.30
234.25
ROA
8.70%
6.41%
7.97%
9.40%
16.91%
18.84%
18.91%
ROE
10.56%
7.82%
9.26%
10.34%
18.61%
20.97%
21.29%
ROCE
14.96%
11.97%
13.63%
14.04%
24.85%
28.00%
27.39%
Fixed Asset Turnover
1.04
1.06
1.55
1.66
2.51
2.49
1.95
Receivable days
96.72
99.92
78.29
97.99
72.40
67.08
83.41
Inventory Days
97.32
108.54
116.00
157.65
102.05
107.06
104.83
Payable days
134.60
138.65
113.80
113.72
74.35
96.63
52.71
Cash Conversion Cycle
59.43
69.81
80.48
141.92
100.10
77.51
135.53
Total Debt/Equity
0.02
0.03
0.04
0.00
0.00
0.00
0.00
Interest Cover
45.01
26.30
44.23
142.61
309.77
392.33
139.24

News Update:


  • USFDA completes routine GMP inspection at Gland Pharma’s Visakhapatnam facility
    2nd Sep 2026, 12:26 PM

    The inspection was concluded with ZERO Form 483 Observations

    Read More
  • Gland Pharma reports 47% jump in Q1 consolidated net profit
    11th Aug 2026, 12:00 PM

    The total consolidated income of the company has increased by 19.09% at Rs 1,861.50 crore for Q1FY27

    Read More
  • Gland Pharma - Quarterly Results
    11th Aug 2026, 00:00 AM

    Read More
  • Gland Pharma executes strategic agreement with Global Pharmaceutical Company
    10th Aug 2026, 09:08 AM

    The agreement is for the technology transfer, manufacturing and supply of a portfolio of sterile injectable products for global markets

    Read More
  • Gland Pharma, Neuland Laboratories join forces for sterile API manufacturing
    6th Aug 2026, 10:10 AM

    The company will establish a sterile manufacturing suite for APIs pertaining to microparticle depot products

    Read More
  • Gland Pharma gets USFDA’s approval for Sugammadex Injection
    29th Jul 2026, 12:44 PM

    According to IQVIA, the product had US sales of approximately $1.6 billion for the twelve months ending April 2026

    Read More

Source: www.accordfintech.com | DISCLAIMER: Information is provided " as is" and solely for informational purposes, not for trading purposes or advice, and may be delayed.